TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00717496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Support Intervention to Improve Breastfeeding
Description: The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
Study: NCT01761669

Intervention type: DRUG
Intervention: Vitamin D
Study: NCT01052454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: Participants in the MBSR arm attend eight weekly classes.
Study: NCT01628237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparison of spinal cord stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comparison of spinal cord stimulation
Study: NCT03855891

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood test
Description: Blood test for spectrum and level of cardiospecific micro-RNA
Study: NCT03616639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
Study: NCT00346151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: 10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Description: 1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: 500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
Study: NCT01018836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riluzole
Description: The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole-brain radiation therapy
Description: Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
Study: NCT02744859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label Condition
Description: Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label Condition
Description: Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label Condition
Description: Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
Study: NCT04776746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trofinetide
Description: Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
Study: NCT03047707

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: S-Shearwave and TE
Description: S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
Study: NCT01728350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE - Helping Others through Purpose and Engagement
Study: NCT00369824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Different formulations of GSK Biologicals' HPV vaccine (580299)
Description: Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
Study: NCT02537301

Intervention type: OTHER
Intervention: joining in the platform
Description: The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
Study: NCT03765541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: In combination with intensive chemotherapy amsacrine-cytarabine:~* Induction (1 cycle): 10 mg/12h from Day 1 to Day 3 of cycle (2 infusions/24h, slow IV \[10 minutes\])~* Consolidation (3 cycles): 10 mg/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[10 minutes\])~In combination with azacitidine:~* Cycle 1: 20 mg/24h from Day 1 to Day 3 of cycle (1 infusion/24h, slow IV \[10 minutes\]).~* Subsequent cycles: 20 mg/24h on Day 1 of each cycle (1 infusion/24h, slow IV \[10minutes\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amsacrine
Description: * Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV \[3 hours\])~* Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV \[3 hours\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amsacrine
Description: * Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV \[3 hours\])~* Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV \[3 hours\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Patients \< 60 years of age:~* Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV \[2 hours\])~* Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[2 hours\]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h
Study: NCT04111588

Intervention type: OTHER
Intervention: Diagnostic Amino acid PET/MRI examination
Description: Diagnostic Amino acid PET/MRI examination
Study: NCT00929617

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental 1: exercise with 2 counseling types
Description: Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
Study: NCT03765541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Patients \< 60 years of age:~* Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV \[2 hours\])~* Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV \[2 hours\]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2/24h from Day 1 to Day 7 of each cycle \[or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle\] (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: 75 mg/m2/24h from Day 1 to Day 7 of each cycle \[or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle\] (SC)
Study: NCT01073280

Intervention type: PROCEDURE
Intervention: cerebral flexible endoscopy
Description: The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
Study: NCT04408859

Intervention type: DRUG
Intervention: Neoadjuvant Chemotherapy
Description: The patients receive neoadjuvant chemotherapy for 2-4 cycles before surgery.
Study: NCT00929617

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care - written materials
Description: Patients will receive written materials about exercise for cancer survivors
Study: NCT03058965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MNI-958
Description: Subjects will undergo PET imaging using \[18F\]MNI-958, a PET radioligand for imaging tau.
Study: NCT00997048

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laying open
Description: Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus excision
Description: Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
Study: NCT03055403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M201-A Injection
Description: Active Substance: M201-A Route of administration: continuous intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline Placebo for M201-A Route of administration: continuous intravenous injection
Study: NCT02330549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc 150 mg
Description: Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching CVC administered orally once daily and taken every morning with food.
Study: NCT02754830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3303560 - IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3303560 - SC
Description: Administered SC
Study: NCT00813514

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VEGF genotyping
Description: blood sample for gene analysis
Study: NCT00204997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian transposition
Description: Laparoscopic ovarian transposition
Study: NCT02073435

Intervention type: BEHAVIORAL
Intervention: Donor pain management
Description: The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~* Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~* Bowel preparation (e.g. Colace or Golytely)~* Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~* Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~* I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is \> 500cc)~* I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~* NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~* Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression
Study: NCT04415567

Intervention type: DRUG
Intervention: Lenvatinib
Description: The patients in lenvatinib group received oral lenvatinib (Eisai, Japan) 12 mg/day (for bodyweight (BW) ≥60 kg) or 8 mg/day (for BW \<60 kg) in 28-day cycles until HCC recurrence or serious adverse events (SAEs) or voluntary withdrawal. Dose interruptions followed by reductions for lenvatinib-related toxicities (to 8 mg and 4 mg/day, or 4 mg every other day) were permitted. All 14 patients took lenvatinib for more than 3 cycles.
Study: NCT03338517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Helium Neon Laser
Study: NCT04820543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of Botulinum type A
Description: The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of Botulinum type A
Description: The participates were allocated to two different application methods: Simplified Method for the first injection and Individualized Method 8 months later. All the patients underwent twice injection with each methods with no change of the BTX-A(Botox, Allergan, Irvine, CA) and other injection details: Lyophilized 100 U of Botox was reconstituted in 2.5 mL of 0.9% sodium chloride solution. The injections were made with a 27-gauge insulin syringe. The treatment was an outpatient procedure and all injections were performed by one of the authors (X.G.). No anesthesia was given during the procedure.
Study: NCT02500238

Intervention type: OTHER
Intervention: Saliva sample
Description: All participants will provide a saliva sample.
Study: NCT03058965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetapir
Description: Subjects with Alzheimer's disease will receive a \[18F\]florbetapir scan to compare distribution of tau in the brain compared to that of \[18F\]MNI-958.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaTscan
Description: DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
Study: NCT02500238

Intervention type: OTHER
Intervention: Saliva sample
Description: All participants will provide a saliva sample.

Intervention type: OTHER
Intervention: Saliva sample
Description: All participants will provide a saliva sample.

Intervention type: OTHER
Intervention: Urine Sample
Description: All participants will provide a urine sample.

Intervention type: OTHER
Intervention: Urine Sample
Description: All participants will provide a urine sample.

Intervention type: OTHER
Intervention: Urine Sample
Description: All participants will provide a urine sample.

Intervention type: OTHER
Intervention: Toe nail clippings
Description: All participants will provide toe nail clippings.

Intervention type: OTHER
Intervention: Toe nail clippings
Description: All participants will provide toe nail clippings.
Study: NCT04089865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.
Study: NCT02500238

Intervention type: OTHER
Intervention: Toe nail clippings
Description: All participants will provide toe nail clippings.

Intervention type: OTHER
Intervention: Breath carbon monoxide test
Description: All participants will provide breath carbon monoxide tests

Intervention type: OTHER
Intervention: Breath carbon monoxide test
Description: All participants will provide breath carbon monoxide tests

Intervention type: OTHER
Intervention: Breath carbon monoxide test
Description: All participants will provide breath carbon monoxide tests
Study: NCT05091294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic injection rate in spinal anesthesia
Description: Administering intrathecal local anesthetics for all patients according to height and weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic injection rate in spinal anesthesia
Description: Administering intrathecal local anesthetics for all patients according to height and weight.
Study: NCT02352792

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiochemotherapy with 70 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy with 77 Gy
Study: NCT02570763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS stimulation
Study: NCT04596280

Intervention type: PROCEDURE
Intervention: Colonic Resection
Description: Resection of the colonic tract which has been interested by the acute diverticulitis

Intervention type: PROCEDURE
Intervention: Colonic Resection
Description: Resection of the colonic tract which has been interested by the acute diverticulitis
Study: NCT03247543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200mg SPN-812
Description: 200mg SPN-812 was administered once daily and compared to placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400mg SPN-812
Description: 400mg SPN-812 was administered once daily and compared to placebo
Study: NCT00491517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Antihypertensive drugs for patients with high blood pressure.
Study: NCT00717626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS
Description: Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is \< 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
Study: NCT00145743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physio,pain,psychotherapy;social,nutrit.counselling&sports
Description: profile and treatment recommendations based on the profile vs. routine psychooncology

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physio,pain,psychotherapy;social,nutrit.counselling&sports
Description: profile and treatment recommendations based on the profile vs. routine psychooncology
Study: NCT03162978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT + POE
Description: Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT only
Description: Subjects will participate in high-intensity interval training (HIIT) only.
Study: NCT00360451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent only Penn Resiliency Program (Adolescent PRP)
Description: In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent only Penn Resiliency Program (Adolescent PRP)
Description: In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Penn Resiliency Program (Parent PRP)
Description: Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
Study: NCT01340079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual world
Description: health education using virtual world Second Life
Study: NCT02133196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young TIL
Description: Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
Study: NCT01340079

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: face to face
Description: health education delivered in face to face groups
Study: NCT01373060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03647124

Intervention type: DRUG
Intervention: Lenalidomide
Description: Specified dose on specified days